Internal Medicine and Hepatology Division, Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, Baronissi, 84081 Salerno, Italy.
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, 84081 Salerno, Italy.
Nutrients. 2021 Mar 13;13(3):933. doi: 10.3390/nu13030933.
Many studies have shown that resveratrol has a lot of therapeutic effects on liver disorders. Its administration can significantly increase the survival rate after liver transplantation, reduce fat deposition and ischemia-induced necrosis and apoptosis in Wistar rats. Resveratrol can provide Liver protection against chemical, cholestatic, and alcohol-mediated damage. It can improve glucose metabolism and lipid profile, reduce liver fibrosis, and steatosis. Additionally, it is capable of altering the fatty acid composition of the liver cells. Resveratrol may be a potential treatment option for the management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant, and calorie-restricting effects. There are also studies that have evaluated the effect of resveratrol on lipid and liver enzyme profiles among patients with metabolic syndrome (MetS) and related disorders. Based on the extent of liver disease worldwide and the need to find new treatment possibilities, this review critically examines current in vitro and in vivo preclinical studies and human clinical studies related to liver protection.
许多研究表明,白藜芦醇对肝脏疾病有很多治疗作用。其给药可以显著提高肝移植后的存活率,减少 Wistar 大鼠的脂肪沉积和缺血性坏死和凋亡。白藜芦醇可以为化学、胆汁淤积和酒精介导的损伤提供肝脏保护。它可以改善葡萄糖代谢和脂质谱,减少肝纤维化和脂肪变性。此外,它能够改变肝细胞的脂肪酸组成。由于其抗炎、抗氧化和限制热量的作用,白藜芦醇可能是治疗非酒精性脂肪性肝病(NAFLD)的潜在选择。也有研究评估了白藜芦醇对代谢综合征(MetS)和相关疾病患者的血脂和肝酶谱的影响。鉴于全球范围内的肝病程度以及寻找新的治疗可能性的需要,本综述批判性地审查了与肝脏保护相关的当前体外和体内临床前研究和人体临床研究。